Mumps virus strain B level jeryl lynn live antigen
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Mumps virus strain B level jeryl lynn live antigen is a vaccine used to prevent Mumps.
- Brand Names
- M-M-R II, Proquad
- Generic Name
- Mumps virus strain B level jeryl lynn live antigen
- DrugBank Accession Number
- DB10316
- Background
Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Mumps virus vaccine live attenuated (Jeryl Lynn strain)
- Mumps Virus Vaccine Live, Jeryl Lynn Strain
Pharmacology
- Indication
Mumps virus vaccine is used to prevent mumps in combination with other virus vaccines, such as the rubella and measles virus vaccine.1,2
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to prevent Mumps •••••••••••• ••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Alemtuzumab. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Mumpsvax Powder, for solution 5000 unit / 0.5 mL Subcutaneous Merck Frosst Canada & Cie, Merck Frosst Canada & Co. 1969-12-31 2004-08-27 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image M-M-R II Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL) + Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Rubella virus vaccine (1000 TCID50/0.5mL) Powder, for solution Subcutaneous Merck Ltd. 1979-12-31 Not applicable Canada M-M-R II Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous A-S Medication Solutions 1971-04-21 Not applicable US M-M-R II Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Physicians Total Care, Inc. 1996-08-07 2012-06-30 US M-M-R II Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Merck Sharp & Dohme Llc 1971-04-21 Not applicable US M-M-R II VACCINE Mumps virus strain B level jeryl lynn live antigen (12500 CCID50/0.5mL) + Measles virus vaccine live attenuated (1000 CCID50/0.5mL) + Rubella virus vaccine (1000 CCID50/0.5mL) Injection, powder, for solution Subcutaneous MSD PHARMA (SINGAPORE) PTE. LTD. 1988-06-24 Not applicable Singapore
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 47QB6MX9KU
- CAS number
- Not Available
References
- General References
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Flu caused by Influenza / Mumps 1 4 Completed Not Available Rheumatoid Arthritis, Juvenile 1 4 Completed Prevention Adverse Event Following Immunization / Measles / Mumps / Rubella 1 4 Completed Prevention BCG Infection / Immune Responses / Vaccine Reaction 1 4 Completed Prevention Hepatitis A Virus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Subcutaneous Injection, powder, lyophilized, for suspension Subcutaneous Powder, for solution Subcutaneous Injection, powder, for solution Subcutaneous 1000 CCID50/0.5mL Injection, powder, for suspension Intramuscular; Subcutaneous Powder, for solution Subcutaneous 5000 unit / 0.5 mL Injection, powder, for solution Subcutaneous Kit; powder, for solution Intramuscular; Subcutaneous Injection, solution Intramuscular; Subcutaneous Injection, powder, for solution Intramuscular; Subcutaneous Injection Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous Powder, for solution Intramuscular; Subcutaneous Injection, powder, lyophilized, for suspension Intramuscular; Subcutaneous Injection Subcutaneous Solution Injection, powder, lyophilized, for suspension Powder - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:03 / Updated at March 28, 2024 03:23